ATE392421T1 - Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung - Google Patents
Von pyrazol abgeleitete kinaseinhibitoren und deren verwendungInfo
- Publication number
- ATE392421T1 ATE392421T1 AT02756943T AT02756943T ATE392421T1 AT E392421 T1 ATE392421 T1 AT E392421T1 AT 02756943 T AT02756943 T AT 02756943T AT 02756943 T AT02756943 T AT 02756943T AT E392421 T1 ATE392421 T1 AT E392421T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- kinase inhibitors
- pyrazole
- derived kinase
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30986501P | 2001-08-03 | 2001-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE392421T1 true ATE392421T1 (de) | 2008-05-15 |
Family
ID=23200008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02756943T ATE392421T1 (de) | 2001-08-03 | 2002-08-02 | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung |
Country Status (9)
Country | Link |
---|---|
US (2) | US6750239B2 (de) |
EP (1) | EP1423382B1 (de) |
JP (1) | JP4357295B2 (de) |
AT (1) | ATE392421T1 (de) |
AU (1) | AU2002321910A1 (de) |
CA (1) | CA2456192A1 (de) |
DE (1) | DE60226154T2 (de) |
MX (1) | MXPA04001087A (de) |
WO (1) | WO2003011855A2 (de) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1423382B1 (de) * | 2001-08-03 | 2008-04-16 | Vertex Pharmaceuticals Incorporated | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung |
SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
UA79804C2 (en) * | 2002-07-03 | 2007-07-25 | Janssen Pharmaceutica Nv | Cck-1 receptor modulators |
US7094791B2 (en) * | 2003-07-31 | 2006-08-22 | Avalon Pharmaceuticals, Inc. | Derivatives of 3-hydroxy-pyrrole-2,4-dicarboxylic acid and uses thereof |
CA2536470A1 (en) * | 2003-08-15 | 2005-02-24 | Vertex Pharmaceuticals Incorporated | Pyrrole compositions useful as inhibitors of c-met |
US8247576B2 (en) | 2003-12-23 | 2012-08-21 | Astex Therapeutics Limited | Pyrazole derivatives as protein kinase modulators |
US20070225293A1 (en) * | 2004-04-23 | 2007-09-27 | Ab Science | Use of C-Kit Inhibitors for Treating Fibrosis |
TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
PT1853588E (pt) * | 2005-02-16 | 2008-08-25 | Astrazeneca Ab | Compostos químicos |
US20080287437A1 (en) * | 2005-05-16 | 2008-11-20 | Astrazeneca Ab | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors |
WO2006136823A1 (en) * | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
US8343953B2 (en) | 2005-06-22 | 2013-01-01 | Astex Therapeutics Limited | Pharmaceutical compounds |
US8541461B2 (en) | 2005-06-23 | 2013-09-24 | Astex Therapeutics Limited | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators |
PL1945631T3 (pl) * | 2005-10-28 | 2012-12-31 | Astrazeneca Ab | Pochodne 4-(3-aminopirazolo)pirymidyny do stosowania jako inhibitory kinazy tyrozynowej do leczenia raka |
US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
MX2008008320A (es) * | 2005-12-23 | 2008-09-03 | Smithkline Beecham Corp | Inhibidores de azaindol de aurora cinasas. |
JP2009528280A (ja) | 2006-02-16 | 2009-08-06 | シェーリング コーポレイション | Erkインヒビターとしてのピロリジン誘導体 |
US8173365B2 (en) | 2006-03-24 | 2012-05-08 | The University Of Tokyo | Method for inhibiting signal transduction, signal transduction inhibitor to be used therein and use thereof |
US8420690B2 (en) * | 2007-02-07 | 2013-04-16 | Glaxosmithkline Llc | Inhibitors of Akt activity |
UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
GB0704932D0 (en) | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
EP2155742A1 (de) * | 2007-04-18 | 2010-02-24 | AstraZeneca AB | 5-aminopyrazol-3-yl-3h-imidazo[4,5-b]pyridinderivate und ihre verwendung zur behandlung von krebs |
UA99459C2 (en) * | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
ES2369596T3 (es) * | 2007-05-04 | 2011-12-02 | Astrazeneca Ab | Derivados de amino-tiazolil-pirimidina y su uso para el tratamiento del cáncer. |
MX2010009268A (es) | 2008-02-21 | 2010-09-14 | Schering Corp | Compuestos que son inhibidores de erk. |
KR20110017445A (ko) * | 2008-06-11 | 2011-02-21 | 아스트라제네카 아베 | 암 및 골수증식성 장애의 치료에 유용한 트리시클릭 2,4-디아미노-l,3,5-트리아진 유도체 |
EP2306825A4 (de) * | 2008-06-26 | 2011-12-28 | Glaxosmithkline Llc | Hemmer der akt-aktivität |
WO2009158373A1 (en) * | 2008-06-26 | 2009-12-30 | Smithkline Beecham Corporation | Inhibitors of akt activity |
KR20110071098A (ko) * | 2008-09-30 | 2011-06-28 | 아스트라제네카 아베 | 복소환 jak 키나제 억제제 |
PE20120003A1 (es) | 2009-01-30 | 2012-02-12 | Glaxosmithkline Llc | Hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil)etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida cristalino |
JP5986098B2 (ja) * | 2010-11-24 | 2016-09-06 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | インテグリン結合キナーゼ阻害剤 |
EP3799871B1 (de) | 2011-10-11 | 2024-02-28 | Dana Farber Cancer Institute, Inc. | Pyrazol-3-one zur aktivierung von pro-apoptotischem bax |
US20160018399A1 (en) | 2013-03-08 | 2016-01-21 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating mammals having lung adenocarcinoma characterized by neuroendocrine differentiation |
CN116115818B (zh) * | 2021-11-12 | 2024-06-28 | 重庆百迈腾世医药科技有限公司 | 活性金属微球、基于活性金属微球的复合栓塞剂及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5837719A (en) * | 1995-08-10 | 1998-11-17 | Merck & Co., Inc. | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
EP1019394A1 (de) | 1997-05-22 | 2000-07-19 | G.D. Searle & Co. | PYRAZOLDERIVATE ALS p38-KINASE-INHIBITOREN |
US6087496A (en) * | 1998-05-22 | 2000-07-11 | G. D. Searle & Co. | Substituted pyrazoles suitable as p38 kinase inhibitors |
BR0104424A (pt) * | 2000-02-05 | 2002-01-08 | Vertex Pharma | Composições de pirazol úteis como inibidores de erk |
EP1423382B1 (de) * | 2001-08-03 | 2008-04-16 | Vertex Pharmaceuticals Incorporated | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung |
-
2002
- 2002-08-02 EP EP02756943A patent/EP1423382B1/de not_active Expired - Lifetime
- 2002-08-02 JP JP2003517047A patent/JP4357295B2/ja not_active Expired - Fee Related
- 2002-08-02 CA CA002456192A patent/CA2456192A1/en not_active Abandoned
- 2002-08-02 AU AU2002321910A patent/AU2002321910A1/en not_active Abandoned
- 2002-08-02 MX MXPA04001087A patent/MXPA04001087A/es unknown
- 2002-08-02 AT AT02756943T patent/ATE392421T1/de not_active IP Right Cessation
- 2002-08-02 US US10/212,294 patent/US6750239B2/en not_active Expired - Fee Related
- 2002-08-02 WO PCT/US2002/024725 patent/WO2003011855A2/en active Application Filing
- 2002-08-02 DE DE60226154T patent/DE60226154T2/de not_active Expired - Lifetime
-
2004
- 2004-05-03 US US10/837,848 patent/US7183307B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2456192A1 (en) | 2003-02-13 |
US6750239B2 (en) | 2004-06-15 |
MXPA04001087A (es) | 2004-07-08 |
JP2005500353A (ja) | 2005-01-06 |
EP1423382A2 (de) | 2004-06-02 |
JP4357295B2 (ja) | 2009-11-04 |
WO2003011855A3 (en) | 2003-09-25 |
DE60226154T2 (de) | 2009-05-20 |
US20030144337A1 (en) | 2003-07-31 |
DE60226154D1 (de) | 2008-05-29 |
WO2003011855A2 (en) | 2003-02-13 |
US7183307B2 (en) | 2007-02-27 |
AU2002321910A1 (en) | 2003-02-17 |
US20040209935A1 (en) | 2004-10-21 |
EP1423382B1 (de) | 2008-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE392421T1 (de) | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung | |
ATE491701T1 (de) | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung | |
DE60122176D1 (de) | Isoxazole und ihre verwendung als erk-inhibitoren | |
MXPA03009846A (es) | Derivados de triazol inhibidores de cinasa y usos de los mismos. | |
WO2002088090A3 (en) | Pyrazole derived kinase inhibitors | |
WO2001056993A3 (en) | Pyrazole compositions useful as inhibitors of erk | |
LT2001103A (en) | Pyrazole compositions useful as inhibitors of erk | |
AP2003002853A0 (en) | Heterocyclic inhibitors of ERK2 and uses thereof | |
ATE339418T1 (de) | Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen | |
DE60315146D1 (de) | Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase | |
RS95404A (en) | Thiazolidinones and the use thereof as polo-like kinase inhibitors | |
CY1112100T1 (el) | ΝΕΑ ΕΝΩΣΗ ΤΡΙΣΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ 8Η-ΠΥΡΙΔΟ[2,3-d]ΠΥΡΙΜΙΔΙΝ-7-ΟΝΗΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΑΣΘΕΝΕΙΩΝ, ΟΙ ΟΠΟΙΕΣ ΕΧΟΥΝ ΠΡΟΚΛΗΘΕΙ ΜΕ ΤΗ ΜΕΣΟΛΑΒΗΣΗ CSBP/p38 ΚΙΝΑΣΗΣ | |
PL373645A1 (en) | Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors | |
ATE495155T1 (de) | Heterocyclische inhibitoren von mek | |
ATE413388T1 (de) | Muskarin antagonisten | |
DE60205776T2 (de) | Indolinon-derivative als protein-kinasehemmer | |
DE50208918D1 (de) | 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung | |
DE60106409D1 (de) | 3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen | |
NO20045025L (no) | Nye forbindelser | |
ATE287886T1 (de) | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer | |
EA200301101A1 (ru) | Производные пиперазина и их применение в качестве ингибиторов pde4 | |
DE60105618D1 (de) | Dihydroporphyrinderivate und ihre verwendung | |
ATE409191T1 (de) | 1,3-diaza-dibenzoazulene als inhibitoren der produktion von tumornekrosefaktor und zwischenprodukte für deren herstellung | |
CY1110796T1 (el) | Παραγωγα μορφολινης ως αναστολεις επαναπροσληψης νορεπινεφρινης | |
DE60224805D1 (de) | 1-glycinyl-4-(1-methylpiperidin-4-yl)piperazine un |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |